Public Employees Retirement Association of Colorado Sells 375 Shares of Silk Road Medical, Inc (NASDAQ:SILK)

Public Employees Retirement Association of Colorado lowered its position in Silk Road Medical, Inc (NASDAQ:SILK) by 9.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,484 shares of the company’s stock after selling 375 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Silk Road Medical were worth $94,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. State Board of Administration of Florida Retirement System raised its holdings in shares of Silk Road Medical by 9.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 12,065 shares of the company’s stock worth $221,000 after buying an additional 1,090 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Silk Road Medical by 4.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 34,905 shares of the company’s stock worth $640,000 after buying an additional 1,490 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Silk Road Medical by 1,293.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock worth $31,000 after buying an additional 2,342 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Silk Road Medical by 0.4% in the 4th quarter. Bellevue Group AG now owns 1,435,682 shares of the company’s stock worth $17,616,000 after buying an additional 5,120 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Silk Road Medical by 10.1% during the 2nd quarter. Rhumbline Advisers now owns 58,016 shares of the company’s stock valued at $1,569,000 after purchasing an additional 5,327 shares in the last quarter.

Silk Road Medical Stock Down 0.0 %

NASDAQ SILK opened at $27.49 on Monday. The stock has a fifty day moving average of $27.18 and a 200-day moving average of $23.47. The stock has a market capitalization of $1.12 billion, a P/E ratio of -20.07 and a beta of 1.53. Silk Road Medical, Inc has a 52 week low of $6.08 and a 52 week high of $27.51. The company has a debt-to-equity ratio of 0.49, a quick ratio of 6.69 and a current ratio of 7.63.

Silk Road Medical (NASDAQ:SILK) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.04). Silk Road Medical had a negative return on equity of 37.30% and a negative net margin of 29.53%. The company had revenue of $51.20 million during the quarter, compared to the consensus estimate of $49.74 million. During the same quarter in the prior year, the business earned ($0.35) earnings per share. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. On average, equities research analysts forecast that Silk Road Medical, Inc will post -1.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Argus cut Silk Road Medical from a “buy” rating to a “sell” rating in a report on Thursday, July 11th. Stifel Nicolaus reaffirmed a “hold” rating and set a $27.50 price target (up from $23.00) on shares of Silk Road Medical in a report on Wednesday, July 17th. Finally, Lake Street Capital reaffirmed a “hold” rating and set a $27.50 price target (down from $28.00) on shares of Silk Road Medical in a report on Tuesday, June 18th. Two research analysts have rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $20.29.

Insider Transactions at Silk Road Medical

In other news, EVP Kevin M. Klemz sold 2,268 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $27.10, for a total value of $61,462.80. Following the transaction, the executive vice president now directly owns 162,926 shares in the company, valued at approximately $4,415,294.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.90% of the stock is owned by corporate insiders.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.